Latest Featured Products

During this webinar, we will provide a comprehensive overview of several cytokine therapy approaches, development, and clinical application. We will further discuss how Sino Biological can assist in cancer immunotherapy research.

Sino Biological has launched a comprehensive collection of high-quality bioreagents to support the study and application of cytokines.

As a global leading supplier of high-quality recombinant cytokines, Sino Biological offers a comprehensive guide to choosing high-quality cytokines based on applications.

Reduce hold-up volume and maximize throughput to help support and create an optimal environment for healthy cells with Corning’s vacuum filters.

Sino Biological has accumulated rich experience in the development and production of custom antibodies, providing high-quality antibody production services for pharmaceutical enterprises, research institutions, and diagnostic companies, supporting basic research, diagnostic reagent development, biological drug development, and other applications.

Whole transcriptome discovery in the tissue context: Gain a deeper understanding of cellular organization with high-throughput profiling of more than 18,000 genes across whole tissue sections.

As a global leader in the recombinant technology, Sino Biological provides a diverse array of recombinant proteins, antibodies, and ELISA kits to facilitate research and development of cancer treatments that focus on c-Kit and other RTKs (EGFR, VEGFR, PDGFR, c-Met, TrkB, FGFR, and more).

Design Hub is the all-in-one DMTA platform that effectively manages drug design projects from idea creation to implementation.

Discover ioSensory Neurons, precision reprogrammed human iPSC-derived nociceptors from bit.bio. Don’t settle for non-human in vitro models or long, complex differentiation protocols that require toxic reagents. Start running reliable nociception assays with ioSensory Neurons today.

Sino Biological provides a comprehensive range of reagents and services to support the development of CAR-T therapies targeting solid tumors.